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Streptokinase (SK) is a therapeutically important thrombolytic agent. Cardiovascular disease is the first 
cause of adult death worldwide. In Egypt about 13% of the population die every year due to ischemic 
heart disease. In spite of this fact, there is no local production of cardiovascular therapeutics. We 
reported for the first time the expression of a recombinant SK from a local Streptococcus strain. When 
produced on industrial scale this r-SK may substantially contribute to reducing the costs of 
thrombolytic therapy in developing countries. In this study, a highly purified r-SK from Streptococcus 
sp. isolated from Egyptian pharyngitis patients was obtained. The isolated strain was partially identified 
using 16S rDNA sequencing and named Streptococcus sp. SalMarEg. It was found to be 
phylogenetically related to Streptococcus pyogenes. Analysis of the obtained sequence showed high 
similarity with other SK genes. The protein expression in a prokaryotic system obtained a 47-kDa SK 
protein that could be purified using a single-step his-tagged affinity purification chromatography, with 
nearly 80% recovery. The clot lytic activities of both recombinant and commercial SK were similar, thus 
giving the basis to scale up this SK product in order to evaluate the possibilities of its 
commercialization in local and/or regional markets. 
 





Cardiovascular disease is one of the leading causes of 
death worldwide. According to World Health Organization 
(WHO) about 13% of Egyptian population die every year 
due to ischemic heart disease, which is considered the 
first cause of adult death in Egypt. Intravenous throm-
bolysis is the standard therapeutic approach for patients 
with acute myocardial infarction (Murray et al., 2010). 
Streptokinase (SK) is a life-saving clot-dissolving drug 
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heart attack (Banerjee et al., 2004). It is now the leading 
fibrinolytic agent in the treatment of thromboembolic 
conditions (Boersma et al., 2003).  It is known that the 
administration of a thrombolytic agent within six hours of 
the chest pain onset would reduce the risk of death by 
40%. 
SK is a protein secreted to the growth medium by many 
beta-hemolytic Streptococcus strains. SK activates 
plasma plasminogen to plasmin (Malke and Ferretti, 
1984) causing fibrinolysis (Khil et al., 2003; Sun et al., 
2004). Two plasminogen activators that occur naturally in 
the blood are the tissue type (t-PA) and the urokinase 
type (uPA). Both t-PA and uPA are trypsin-like serine 
proteases, which activate plasminogen directly (Coleman 
et al., 2005). 
Currently, despite the wide use  of  tissue  plasminogen  




activators in developed countries, SK remains essential 
to the management of acute myocardial infarction in 
developing nations (Sikri and Bardia, 2007). In Egypt, 
there are no specialized biotechnology firms and most 
pharmaceutical products are imported in bulk and then 
packaged in the country. Therefore, for socio-economical 
reasons, local biotechnological production of SK in Egypt 
would substantially contribute to reducing the costs of this 
important thrombolytic agent. 
Native SK is a single chain polypeptide with a mole-
cular weight of 47 kDa. The protein consists of 415 amino 
acid residues in a single polypeptide chain. Due to the 
pathogenicity of its natural host, the gene encoding SK 
has been cloned and expressed in several heterologous 
hosts such as Escherichia coli (Malke and Ferretti, 1984; 
Malke et al., 2000; Yazdani and Mukherjee 2002), 
Bacillus subtilis (Wong et al., 1994), Lactococcus lactis 
(Sriraman and Jayaraman, 2006), Pichia pastoris (Pratap 
et al., 2000), and Streptomyces lividans (Kim et al., 
2010). On the other hand, hemolytic streptococci secrete 
several toxins that complicate the downstream purify-
cation (Pimienta et al., 2007). 
Several affinity chromatography methods have been 
discussed for purifying SK. The earliest of such proce-
dures used insolubilized di-isopropyl fluorophosphates 
(DIP) plasmin as the affinity ligand (Castellino et al., 
1976). Purification through the affinity column caused a 
30% decrease in the streptokinase activity. Different 
affinity purification methods used a monoclonal antibody 
ligand (Andreas, 1990; Babashamsi et al., 2009), 
acylated plasminogen or plasmin as the affinity ligand, or 
a combination of human plasminogen and monoclonal 
antibody against SK for chromatographic purification 
(Rodriguez et al., 1994). This purification method produced 
a preparation with about 50,000 units of activity per mg of 
protein and a purity of >93%. Since then, highly purified 
SK has become an important tool in fibrinolytic therapy. 
Despite the mentioned advances, the low yield obtained 
in normal SK production and the pathogenicity of its 
natural host were the principal reasons leading to the 
development of a recombinant source. In this study we 
isolated a streptococcal strain from Egyptian pharyngitis 
patients and identified it as Streptococcus sp. SalMarEg 
using 16S rDNA sequencing. We amplified a full coding 
SK sequence using primers flanking the complete coding 
sequence of other Streptococcus species and cloned the 
product in E. coli. The recombinant product was then 
expressed in a prokaryotic expression system and ob-
tained the purified SK protein (10 µg/ml) in a bioactive 
form with similar activity to commercial SK. To our know-
ledge, this is the first attempt to produce recombinant SK 
from local Egyptian species. 
 
 
MATERIALS AND METHODS 
 
Bacterial isolation, selection and culture 
 





biology Department (Medical Research Institute, Alexandria 
University), and streaked on blood agar plate (Oxoid Ltd., 
Hampshire, United Kingdom) with Streptococcus selective media.  
Single colonies were streaked again on blood agar plates and 
incubated at 37°C overnight in order to estimate its hemolytic 
activity (agar plate contained 5 to 10% human blood). β-Hemolytic 
activity is associated with complete lysis of red blood cells. The 
colony with the highest hemolytic activity was inoculated in 5 ml of 
LB broth and incubated overnight at 37°C. The culture was 
subsequently inoculated into 50 ml of LB broth. 
 
 
Identification of the Streptococcus sp. SalMarEg 
 
Bacterial genomic DNA was extracted from an overnight bacterial 
culture using QIAGEN DNA extraction kit according to the 
manufacturer's protocol. The 16S rDNA was amplified from the 
bacterial genomic DNA using a 16S rDNA universal primer pair: 
1155F: 5'-AAC TGG AGG AAG GTG GGG AT-3' (gb| HQ658085.1) 
R: 5'-AGG AGG TGA TCC AAC CGC A-3' according to Innis et al. 
(1990). PCR was performed in a total volume of 50 µl containing 5 
µl of 5× Green Go Taq flexi buffer (Promega, USA ), 5 µl of 5× 
colorless Go Taq flexi buffer (Promega, USA), 5 µl MgCl2 (25 mM) 
(Promega, USA), 2 µl of dNTP mixture (10  mM of each) (BIORON, 
Germany), 50 ng  bacterial genomic DNA as template, 4 µl of each 
primer (20 pmol/µl) and 2 U Taq polymerase (5 U/µl)  (Promega, 
USA). The volume was completed to 50 µl with sterile ddH2O. The 
PCR thermal profile used to amplify 16S rDNA was as follows: initial 
denaturation step at 95°C for 3 min, followed by 35 cycles of 
amplification with denaturation at 95°C for 1 min, annealing at 55°C 
for 1 min and extension at 72°C for 1 min ending with extension at 
72°C for 10 min. PCR amplification was performed using a thermo-
cycler (MJ Research, model PTC-200 Peltier, USA). Purification of 
the amplified 16S rDNA fragment was performed using QIAquick 
PCR purification kit according to manufacturer’s instructions. 
Sequencing of the 16S fragment was carried out by MACROGEN, 
Korea using the 16S rDNA forward primer.  Alignment of 16S rDNA 
sequence was conducted using CLUSTAL W (1.83) multiple 
sequence alignment software (Thompson et al., 1994; Larkin et al., 
2007). Phylogenetic tree and molecular evolutionary analyses were 
performed according to NCBI nucleotide BLAST, genbank database 
and generated by CLC Genomics workbench-3. 
 
 
Amplification, cloning and sequencing of the SK gene 
 
A specific SK primer pair flanking the complete coding sequence 
was designed using DNA star software from about 218 DNA 
sequences representing genes from different streptokinase species 
selected from GenBank: 1F 5'-TAC TAA CGA CCT GGA CTC AC -
3’ and 1248R 5'-TAT TGG GAT TGC TG TTT ATT-3' 
(Streptococcus dysgalactiae subsp. equisimilis strain 04/04 strepto-
kinase gene, complete coding sequence (gb| HQ629621.1). Gene 
amplification was carried out using standard PCR as described 
above, however with annealing temperature of 51°C. The amplified 
PCR product was purified using the EzWay
TM
Gel Extraction kit 










, USA). The insert was verified by DNA 
sequencing (MACROGEN, Korea) using the following forward 
primer 442F 5'-GGT TTA GTT CAT GTA TCG-3'.  
 
 
Expression of SK gene 
 
The cloned SK gene was released from the pCR® 2.1-TOPO® 
vector using EcoRI restriction enzyme, and purified using 
EzWay
TM





the linearized prokaryotic expression vector pPROEX
TM
 HT 
according to the manufacturer's protocol. The pPROEX
TM
 HT 
Prokaryotic Expression System was designed for expression of 
foreign proteins fused to a 6 × histidine sequence (His)6 for affinity 
purification (Life Technologies, Inc. by QIAGEN, Inc., USA) 
(Hoffman and Roeder, 1991). E. coli strain DH5α competent cells 
were used in this study for subcloning of r-SK. Expression of r-SK 
was induced using Isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
as follows: a single colony of sub-cloning transformation reaction 
was inoculated into 2 ml of LB media containing 100 µg/ml 
ampicilin. The culture was incubated overnight at 37°C. 10 ml of LB 
media containing100 µg/ml ampicilin were inoculated with 0.1 ml of 
overnight culture and allowed to grow at 37°C. When the culture 
reached an A590 of 0.5 to 1.0, 1 ml was removed and centrifuged for 
1 min in a microcentrifuge (Hittich MIKRO 20, Germany). The 
supernatant was discarded and pellets resuspended in 100 µl of 
PBS and designated as (the uninduced sample). The remaining 
culture was induced by addition of IPTG to a final concentration of 
0.6 mM and incubated as mentioned before. 1 ml culture was 
removed after 1, 2, 3 h after induction and OD measured at A590. 
The cells were centrifuged as described above and the pellets 
resuspended in 100 µl of PBS and designated (the induced 
sample). 20 µl of each induced and non induced samples were 
mixed with an equal volume of 2X SDS sample buffer, boiled and 
were analyzed by SDS-polyacrylamide gel electrophoresis. 
 
 
Affinity purification of 6X Histidine-tagged r-SK 
 
The expressed r-SK fused to 6x His residue has a strong affinity 
against Ni-NTA resin matrix (QIAGEN, Inc., USA) (Hoffman and 
Roeder, 1991) that specifically binds His-tagged proteins. The 
induced bacterial cells were collected and resuspended in 4 
volumes of lysis buffer [50 mM Tris-HCl (pH 8.5 at 4°C), 100 mM 
KCl, 5 mM β-mercaptoethanol, 1 mM PMSF]. The suspension was 
lysed by sonication, the cell debris removed by centrifugation and 
the supernatant transferred to a fresh tube (crude supernatant). 
Affinity purification was performed according to the manufacturer's 
protocols (QIAGEN NI-NTA affinity purification kit). The column was 
equilibrated with column binding buffer. The crude sample was 
loaded onto the column, which was washed with 10 volumes of 
binding buffer, then 2 volumes of wash buffer, followed by 2 
volumes of binding buffer. The bound proteins were eluted with 
elution buffer (Life Technologies, Inc. by QIAGEN, Inc., USA). 
 
 
Determination of r-SK concentration 
 
Protein concentration was estimated in the elution fraction by 
Bradford assay. A standard curve was made using bovine serum 
albumin (BSA) with different concentrations (0, 2.5, 5, 7.5, 10, 12.5, 
15, 17.5 and 20 µg/ml). 40 µl of dye stock were mixed with 160 µl of 
protein standard solution or samples to be assayed and incubated 
for 10 min. Absorbance was then measured at 595 nm in a spectro-
photometer (Perkin Eimer, lambda EZ 20l, USA). The total protein 




Solubilization and renaturation of r-SK inclusion bodies 
 
In this study, r-SK was expressed as insoluble inclusion bodies 
(inactive form), which required renaturation as follows: the inclusion 
pellets were solubilized in 8 M urea buffer at pH 8. The mixture was 
incubated at 25°C for 1 h before the insoluble parts were removed 
by centrifugation. The solution was then diluted with phosphate 
buffer (pH 10.7) for SK renaturation. The solution was transferred 
for dialysis against the buffer [20 mM Tris/HCl pH 8.0, 50 mM NaCl,  




1 mM EDTA] at 4°C overnight. The folded SK was then assayed as 
thrombolytic agent. Using this procedure, approximately 3.0 mg of 
enzymatically active SK was obtained from 1 g wet weight. 
 
 
Gel electrophoresis and Western blotting 
 
Protein samples were prepared and run on 12% SDS-poly-
acrylamide gel in the presence of pre-stained molecular weight 
markers (14 to 116.0 kDa) (Jena Bioscience, Germany). Proteins 
were then transferred to a nitrocellulose membrane (Costa, Bio 
Blot, Canada) for 1 h at 0.3 A, and detection was performed using 
BCIP/NBT liquid Substrate System (Sigma, USA). 
 
 




Samples were run on 12% of PAGE with PBS but water in the 
separating gel was replaced by human plasma diluted (1:5). After 
running, the gel was soaked in 1% Triton X100 for 2 h. The solution 
was changed every 1 h to remove SDS for renaturation of the 
enzyme. The gel was then washed three times with tap water and 
soaked in universal buffer pH 8 for 2 h at 37°C. The gel was then 
stained with Coomassie blue stain overnight (0.25%, w/v) in 




Quantitative assay for determination of r-SK activity  
 
R-SK activity was estimated as units/mg using a simple quantitative 
colorimetric method. A standard curve was made using commercial 
SK with different known concentrations diluted from a stock of (1 
mg/ml) as follows: (1:1, 1:2, 1:3, 1:4, 1:5, 1:6, and 1:7). The 
principle of the assay is based on the release of Coomassie brilliant 
blue R-250 dye from the clot on applying SK as thrombolytic agent. 
30 µl of freshly prepared Coomassie brilliant blue R-250 (1 mg/ml) 
was added to 200 µl of the diluted human plasma (1:5, v/v) and 
mixed. 100 µl of thrombin (Sigma, USA) (2.5 units/ml) were then 
added to facilitate the formation of a plasma clot. Subsequently, 1 
ml of commercial SK standard (Sigma, USA) (0.1 mg/ml) was used 
as a plasminogen activator to initiate clot lysis. The mixture was 
incubated for 10 min at 37°C. During the course of lysis, 100 µl of 
soluble material were transferred to microtiter wells and the 
absorbance at 540 nm was determined as a measure of clot lysis 
as shown in Supplementary Figure 1 (Mao and Tucci, 1991).    
 
 
Comparison of clot lysis activity of commercial and r-SK 
 
Venous blood was drawn from 20 healthy people without a history 
of oral contraceptive or anticoagulant therapy. About 500 µl of blood 
were transferred to previously weighed Eppendorf tubes arranged 
in two groups: one group for r-SK and the other for commercial SK 
and incubated at 37°C for 45 min. After clot formation, serum was 
completely removed and each tube was again weighed to 
determine the clot weight (clot weight= weight of clot containing 
tube – weight of the tube alone). 100 µl of r-SK along with various 
dilutions in sterile distilled water were added to the tubes (0.01 0, 
0.008, 0.006, 0.004, 0.002 g/ml) (n=20 for each dilution). Water was 
also added to the other pre-weighted tubes containing clots to serve 
as negative thrombolytic control. The same dilutions were done with 
commercial SK group as positive control in order to assess the 
effectiveness of both SKs as thrombolytic agents. All the tubes 
were then incubated at 37°C for 90 min and observed for clot lysis. 
After incubation, the fluid obtained  was  removed  and  tubes  were  






Figure 1. Quantitative colorimetric assay for determination of r-SK activity. A standard curve was 
made using commercial SK with different known concentrations diluted from a stock of 1 mg/ml. 
These were 3550, 1775, 1183, 887, 710, 591 and 444 units/mg, respectively. X-axis represents 




again weighed. Difference obtained in weight taken before and after 
clot lysis was expressed as mean percentage of clot lysis. The test 
was repeated three times for each dilution of r-SK and commercial 
SK in the blood samples of the 20 different healthy people (Prasad 





Informed consent from pharyngitis patients  and healthy volunteers  
were collected and approved by the ethics committee of the 
medical research institute, Alexandria University, Egypt and,  
therefore the study was performed in accordance with the ethical 






Isolation and identification of Streptococcus sp. 
 
We isolated local Streptococcus species using swabs 
from Egyptian pharyngitis patients, which were routinely 
streaked on blood agar plates. Out of the swabs from five 
pharyngitis patients, we isolated Streptococcus sp. from 
one culture containing about 26 colonies of high β- hemo-
lytic activity. The isolate with the highest β-hemolytic 
activity was selected and its genomic DNA was extracted 
for molecular taxonomy purposes by amplification and 
partial sequencing of the 16S rDNA gene (ca 350 bp) 
using PCR. Sequence analysis revealed that the selected 
isolate belongs to the Streptococcus genus and the 
partial sequence was submitted to GenBank under the 
accession No. FJ490631. Nucleotide BLAST and 
phylogenetic analysis of the submitted sequence 
revealed that it may be a new Streptococcus isolate, and 
it was subsequently called Streptococcus sp. SalMarEg. 
Streptococcus sp. SalMarEg had 99% identity with 
Streptococcus pneumoniae, Streptococcus intermedius, 
Streptococcus sanguinis, Streptococcus anginosus and 




SK gene amplification, cloning and subcloning into 
prokaryotic expression vector 
 
The SK gene was amplified from the genomic DNA of 
Streptococcus sp. SalMarEg using specific SK primers 
flanking the complete coding sequence of other 
Streptococcus sp. (Figure 2A, Lane 2). The PCR  
product(1000-1500 bp) was excised from the gel, purified  






Figure 2. Cloning of SK gene from Streptococcus sp. SalMarEg. One percent agarose gel showing (A) 
lane M, DNA ladder marker (100 bp) (Biron, Germany); Lane 1, negative control of PCR reaction 
(contains water); lane 2, PCR amplification product of SK gene (~1320 bp) from the genomic DNA of 
Streptococcus sp. SalMarEg.; lane 3, SK insert amplified from TOPO cloning vector using SK specific 
primers after cloning the SK PCR product. (B) PCR product amplified from TOPO cloning vector using 
M13 primers. Lane M, DNA ladder marker (100 bp) (Biron, Germany); lane 1, PCR amplification of 
TOPO cloning vector containing no SK insert; lane 2, PCR amplification of TOPO cloning vector 




and cloned in the pCR 2.1-TOPO plasmid vector. We 
screened for the SK insert using streptokinase-specific 
primers, which yielded the expected 1320 bp band 
(Figure 2A , lane 3), as well as with M13 universal 
primers, which yielded a 1520 bp band that included an 
additional 200 bp representing the M13 vector sequence 
(Figure 2B, Lane 1). Next, we digested the plasmid DNA 
with EcoRI to release the insert, which was sub-cloned 
into the prokaryotic expression vector pPROEX
TM 
HT. 
The transformed bacterium was subjected to gene 
induction using IPTG in the culture medium.  
 
 
Sequencing of the recombinant SK and phylogenetic 
analysis 
 
In order to confirm our results, we sequenced the r-SK 
using SK forward primers and submitted the obtained 
partial sequence into GenBank database under the 
accession No. FJ490630. We translated the r-SK 
nucleotide sequence using ExPASY tool (Albar et al., 
2007) and compared its amino acid sequence with that of 
SK from Streptococcus equisimilis, Streptococcus uberis 
and Streptococcus pyogenes using CLUSTAL W (1.83) 
multiple sequence alignment software and Mega4 
software (Tamura et al., 2007). The identity scores were 
82, 25.6 and 90% in the aligned regions, respectively 
(Figure 3). We then used NCBI-BLAST for nucleotide 
sequence alignment and used the results to construct a 
phylogenetic tree using CLC Genomics Workbench-3 
software (Figure 4). 
 
 




 HT expression vector expresses recombinant 
proteins fused with 6x His residues. His-tagged 
recombinant proteins have a great affinity towards Ni-
NTA matrix. In this study, the high affinity concen-tration 
of the recombinant protein enabled single-step 
purification by one step His-tagged affinity purification 
chromatography, with nearly 80% recovery. For the 
assessment of r-SK purity, washing and elution fractions 
were examined using 12% SDS-PAGE (Figure 5A). All 
samples to be examined were pre-heated prior to running 
on gel, and about 30 µl of each sample were loaded. The 
purified r-SK-6-His-Tag was then immunoblotted and 
detected using anti-His-Tag  antibody,  which  gave  a  47  






Figure 3. Comparison of the amino acid sequence of r-SK from Streptococcus sp. SalMarEg. to that of SK from S. equisimilis, 
S. uberis and S. pyogenes using CLUSTAL W (1.83) multiple sequence alignment software and Mega4 software (Tamura et 
al., 2007). The identity (*): 10 is 2.22%, strongly similar; (:): 47 is 10.44%, weakly similar; (.): 28 is 6.22% and different: 365 is 
81.11%. 






Figure 4. Phylogenetic tree of Streptococcus sp. SalMarEg SK gene partial codons generated by CLC Genomics workbench-3 




kDa band (Figure 5B).  
 
 




The renaturation efficiency of r-SK was evaluated using 
zymography. A SK substrate (plasminogen) replaced 
water in the separating gel in SDS-PAGE. Different 
concentrations of r-SK were loaded onto the gel and 
different activities were obtained as shown in Figure 6A. 
 
 
Colorimetric assay  
 
A colorimetric assay for SK activity quantification was 
performed in order to estimate the units (U) of enzyme 
per mg of recombinant protein. According to the standard 
curve from serial dilutions of a commercial SK stock, 




Comparison of clot lysis activity of r-SK and 
commercial SK according to the in vitro model study 
 
To determine the in vitro activity of r-SK to lyse blood 
clots, five different concentrations of r-SK (0.01, 0.008, 
0.006, 0.004 and 0.002 g/ml) for each of the 20 blood 
samples were used. Each experiment was repeated three 
times. Mean percentage of clot lysis was calculated for 
each concentration: these were 72.6, 64.2, 62.9, 59.2, 
56.7% for the five different r-SK dilutions, respectively, 
and 2.2% for the negative control (water). These results 
were almost similar to those of the commercial SK 
(Figure 6B). It was observed that 2000 U/ml of the 
commercial native SK gave the same activity as 1904 





Isolation and identification of Streptococcus sp. 
 
In this study, SK isolated from local Streptococcus sp. 
SalMarEg was efficiently produced in a recombinant 
bioactive form. It is worthy to mention that the binding of 
plasminogen by pathogenic Group C streptococci 
isolated from human, horses, and pigs is specific to the 
homologous host (McCoy et al., 1991). For this reason, 
we isolated Streptococcus sp. from human origin. It has 
been previously reported that SK activity associated with 
the plasminogen activator secreted from S. uberis is 
different from that of S. pyogenes (Lancefield group A) 
and S. equisimilis (Lancefield group C) strains, as it is 
able to activate bovine but not human plasminogen. It 
also differs from that produced by Lancefield group E 
strains because of its inactivity against porcine plas-
minogen (Ward and Leigh, 2004). 
The isolated Streptococcus strain in this study was 
molecularly identified based on 16S rDNA gene 
sequence. In this work, the amplified SK gene from the 
selected isolate's genomic DNA was cloned into an 
expression vector. Previous attempts were made to clone 
SK gene included in vitro cloning by PCR using specific 
SK primers and restriction digestion of the gene from the 
whole genome (Malke and Ferretti, 1984).  In  this  study,  






Figure 5. Affinity purification of r-SK. (A) 12% SDS–PAGE showing affinity purification 
fractions of r-SK.; Lane M, protein molecular weight marker 14.4 to 116 kD; Lane 1, 
uninduced E. coli; Lane 2, IPTG-induced E. coli for r-SK expression; Lane 3, washing fraction 
of affinity purification; Lane 4, elution fraction (r-SK); lane 5, standard native SK (Sigma, 
USA). (B) Western blot analysis of purified r-SK. Lane M; Spectra™ Multicolor Broad Range 
Protein Ladder (10-260 kD) (Fermentas, Canada); Lane 1, r-SK purified fraction detected by 
QIA Express anti His-Tag detection system (ALP labeled); Lane 2, negative control. 






Figure 6. r-SK activity. (A) r-SK activity by zymography. Different concentrations of r-SK were run on 12% 
SDS–PAGE in 1X electrophoresis buffer, stained with coomassie blue R-250 (Alliance bio, USA) and 
photographed. Lane M, protein molecular weight marker 14.4 to116 KD (Jena Bioscience, Germany); lane 1, 
2, 3 and 4 each represents 50, 40, 30, and 20 µl from 0.1 mg/ml of renatured r-SK. (B) Clot lytic activity of r-
SK. histogram showing mean ± SD of clot lytic activities of different concentrations of r-SK in comparison to 
the same concentrations of commercial standard SK (Sigma, USA) using blood samples from normal 
subjects (n=20). SK activity represents the average of three replicates. 




the r-SK protein (fused with 6X His-Tag)  expression  was 
induced by IPTG and the obtained r-SK was sub-
sequently purified. In general, two different strategies for 
the production of enzymatically active SK were reported. 
In the first strategy, SK is expressed as inclusion bodies 
without its signal sequence followed by purification, 
solubilization, and renaturation to obtain an active 
preparation. In the second strategy, enzymatically-active 
SK is secreted into the culture medium. The design of the 
expression strategy depended on process economics, 
regulatory requirements and the end-use of the purified 
protein (such as biochemical studies, structural charac-
terization, and commercial usage as an industrial 
enzyme). In this study, we used the second strategy as it 
supports the biochemical characterization and semi-
industrial approach for the production of r-SK in Egypt. 
 
 
Sequencing of the recombinant streptokinase and 
phylogenetic analysis 
 
Among the currently known SKs, S. uberis seems to be 
the least conserved, since the degrees of identity at the 
nucleotide level for six other streptokinases from 
serological Groups A, C, and G range between 80 and 
98% (Frank et al., 1995). In line with this observation, no 
similarity between SK from Streptococcus sp. SalMarEg 
and SK from S. uberis was found at the nucleotide level 
by BLAST searching. 
The fact that streptococci with different host specifi-
cities produce SK that shows considerable sequence 
diversity but conserved plasminogen activation potential 
indicates that generation of plasmin activity is important 
for the pathogenesis of these bacteria. On the other 
hand, the high degree of amino acid sequence diversity 
also indicates that only a low degree of sequence 
constraint is needed for the ability of SK to activate plas-
minogen. In this study, we used E.coli DH5α strains for 
the high level expression of r-SK.  Mahmoudi et al. (2010) 
used E.coli  BL21 (DE3) plysS strain, which is deficient in 
cytoplasmic protease gene products and, therefore, gives 
high level expression of fusion proteins (Sugimura and 
Higashi, 1988). Other hosts have certain limitations. For 
example, B. subtilis produces a number of extracellular 
proteases, which recognize and degrade heterologous 
proteins. In addition the recombinant vector is largely 
unstable inside the competent Bacillus strain. 
 
 
Purification and activity of r-SK 
 
The possibility to obtain high concentrations of the r-SK 
enabled the single-step purification by His-tagged affinity 
purification chromatography, with nearly 80% recovery. 
To our knowledge, this would be the first report on a 
highly pure r-SK in a single-step purification process. 





purity of r-SK using two-step purification by ion  exchange  
followed by gel filtration chromatography. Ignatova et al. 
(2000) reported purification of excretory r-SK with 51% 
recovery and about 97.8% purity.  
Several affinity chromatography methods have been 
discussed for purifying SK (Castellino et al., 1976; Liu et 
al., 2000). It was concluded that downstream processing 
costs can be considerably reduced and yields of pure 
recombinant protein is enhanced by reducing the number 
of processing steps and increasing the recovery of 
protein product in each step. Inclusion bodies, refolding 
and single-step purification achieves this goal. The whole 
process of expression and purification involves a minimal 
set of procedures and is very useful for economic 
production of proteins with therapeutic significance such 
as SK on a large scale. 
In this study, r-SK was induced as inclusion bodies in a 
small scale. 10 µg/ml was obtained. Expression of r-SK 
as inclusion bodies provides a large quantity of the 
enzyme that can be easily recovered and refolded 
(Azuaga et al., 2002; Balagurunathan et al., 2008). The 
production of recombinant protein as insoluble inclusion 
bodies accumulates about 25% of total cell protein 
compared to the soluble secretory recombinant protein, 
which accumulates up to 15% of total cell protein (Perez 
et al., 1998). 
In this work, we found that 1 mg r-SK contained about 
2950 U. Other studies reported that when r-SK was 
expressed as secreted into the medium or under shake-
flask cultivation method, about 8 to100 U/ml and 55 U/mg 
were obtained, respectively (Malke and Ferretti, 1984). In 
this study, we found that 2000 U/ml of commercial native 
streptokinase gave the same activity as 1904 U/ml of our 
r-SK using an in vitro colorimetric model. Most of the in 
vitro methods that are currently applied to study 
thrombolysis have certain limitations. Some involve 
complex computational and mathematical skills that give 
only theoretical prediction of the outcome and most are 
expensive to be performed in a laboratory. The assay 
used in this study is easy and cost effective (Prasad et 
al., 2006). 
The importance of substitution of expensive imported 
SK by locally produced low cost r-SK is reinforced by the 
notion that not all commercial SK preparations are 
effective (Quriel, 2002). This was demonstrated in a 
comparative study by Hermentin et al. (2005), in which 
they compared the activities of 16 different SK prepa-
rations and found that only three fulfilled the minimum 
requirements of the European Pharmacopoeia 
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